Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 14.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Wednesday, April 15. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Statement of Educational Need, Target Audience, and Learning Objectives
Cancers are communities of cells, including those harboring genetic mutations, aka “tumor” or “cancer” cells, as well as other “normal” cell types activated and/or recruited to the local tumor microenvironment (TME). Components of the TME (e.g., blood and lymphatic vessels, fibroblasts and other mesenchymal support cells, innate and adaptive immune cells, as well as extracellular matrix, hypoxia, and low pH), while regulating or being regulated by hallmark features of cancer development, can also thwart efficacy of cytotoxic, targeted, and immune therapies.
The tumor microenvironment is the tissue comprising normal cells, molecules, and blood vessels that surround and feed tumor cells. Although malignant cancer cells harboring activating mutations in oncogenes or loss of tumor suppressors drive tumor growth, they are supported by a diverse array of leukocytes, fibroblasts, endothelial cells (both blood and lymphatic), and other stromal components. It has been appreciated for some time that tumor blood vessels and the extracellular matrix play a significant role in disease progression. However, there is growing appreciation of the contribution infiltrating immune cells, cancer-associated fibroblasts, macrophages, angiogenic endothelial cells, and stress responses to oxygen play in sustaining cell proliferation, evading growth suppressors, promoting survival, activating invasion and metastasis, and reprogramming energy metabolism.
Tumor microenvironment also plays a role in the cancer recurrence and resistance to chemotherapy, as recently demonstrated in ovarian cancer. Gaining a better understanding of how tumors interact with their microenvironment will allow for novel drug development and could provide the power to overcome acquired resistance to front-line therapies. Presentations during this AACR Special Conference will address the tumor microenvironment and metabolism/metabolic adaptations, immune response, immunity and therapies, metastasis. hematopoietic and cell-cell signaling, carcinogenesis, and the translational potential and therapeutic targets in the tumor microenvironment.
To bridge the gap between scientists and clinician-scientists’ professional practice, this conference will provide a platform for discussion and initiating collaborations for novel therapeutic strategies to address resistance, metastasis, immunity, and metabolism and implementation of new modeling and imaging techniques to improve our understanding of the tumor microenvironment.
After participating in this CME activity, physicians should be able to:
- Explain the potential clinical impact of novel imaging technologies used to assess the tumor microenvironment
- Articulate the role of inflammation on metastasis and the tumor microenvironment
- Assess the contribution of immune cells to tumor progression and growth
- Explain the contribution of metabolic adaptations to cancer progression
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
Acknowledgment of Financial or Other Support
This activity is supported by a Professional Educational Grant from Pfizer. Any others will be disclosed at the activity.
Questions about CME?
Please contact the Office of CME at (215) 440-9300 or email@example.com.